Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Elekta AB ( ($SE:EKTA.B) ) is now available.
Elekta has released its ‘2025 Impact Report’ emphasizing the importance of radiotherapy in modern cancer care. The report advocates for broader adoption and access to advanced radiotherapy, highlighting innovations like adaptive radiotherapy that improve precision and patient outcomes. The report also serves as a resource for cancer patients, showcasing the role of radiotherapy as both a standalone and complementary treatment, and includes patient testimonials demonstrating the benefits of advanced technologies.
The most recent analyst rating on ($SE:EKTA.B) stock is a Hold with a SEK50.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
More about Elekta AB
Elekta is a leader in precision radiation therapy, dedicated to providing access to advanced cancer care. The company collaborates with customers to develop sustainable, outcome-driven, and cost-efficient solutions. Headquartered in Stockholm, Sweden, Elekta operates in over 40 countries and is listed on Nasdaq Stockholm.
Average Trading Volume: 1,081,893
Technical Sentiment Signal: Sell
Current Market Cap: SEK18.67B
See more insights into EKTA.B stock on TipRanks’ Stock Analysis page.